ClinicalTrials.gg
CompletedNCT07824388Updated Sep 17, 2026

Evaluation of the Anti-plaque Effect of a Bioflavonoid-based Antiseptic Mouthwash

A Phase 4 interventional study of Bioflavonoid mouthwash and Chlorhexidine 0.12% mouthwash in Gingival Inflammation and Dental Plaque Accumulation, sponsored by University of Barcelona. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by University of Barcelona · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2026, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies testing chlorhexidine in Gingivitis — 2 open to participants now, 3 under way, 1 of them phase 3. Chlorhexidine · Gingivitis.

Enrollment
17th of 21
24 · median 60
Started
2026
with 2 others
Phase 4
7 of 21
none open now
Registered
21st of 21
by date

Among the 21 studies testing chlorhexidine in Gingivitis, this one is the 17th largest by enrollment, is one of 3 that started in 2026, is one of 7 in phase 4, and was the 21st registered.

Gingivitis

636 studies on the registry are indexed under Gingivitis; 109 are open to participants now.

Browse Gingivitis studies →

Open to participants now

2 of the 21 studies testing chlorhexidine in Gingivitis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About chlorhexidine

Chlorhexidine: first FDA approval 1976 (HIBICLENS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing chlorhexidine in Gingivitis, or all of them as a file.
02

Study summary

This study evaluates the antiplaque efficacy of a bioflavonoid-based mouthwash compared to a positive control (0.12% chlorhexidine mouthwash). Following a baseline oral health assessment, participants will use the assigned mouthwash twice daily for 4 consecutive days while refraining from all mechanical oral hygiene practices (e.g., tooth brushing). The trial follows a 2-phase crossover design, where participants use one mouthwash in the first phase and the other in the second phase, separated by a 15-day washout period.

03

Conditions studied

  • Gingival Inflammation
  • Dental Plaque Accumulation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with > 20 teeth present, with a minimum of 5 teeth per quadrant.
  • Individuals >18 years of age

Exclusion criteria

Exclusion Criteria:

  • Individuals with systemic diseases ( o IV).
  • Individuals with systemic diseases or undergoing pharmacological treatment that may modify gingival health.
  • Individuals with periodontal disease (probing depth > 5mm and/or clinical attachment loss >2mm).
  • Individuals currently under orthodontic treatment.
  • Individuals with removable dental prostheses.
  • Individuals with known allergies to any ingredient in the study mouthwashes.
  • Individuals presenting with oral mucosal lesions.
  • Individuals who have used antibiotics, antifungals, , or within 3 months prior to the study.
  • Individuals who have used chlorhexidine mouthwash or any other oral antiseptic within 15 days prior to the start of the study.
  • Individuals with any active carious lesions or any cervical restorations present on any tooth.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence 1 (Bioflavonoid moutwash then Chlorhexidine)

    Participants receive Bioflavonoid mouthwash twice daily for 4 days in Phase 1, undergo a 15-day washout period, and then receive Chlorhexidine 0.12% mouthwash twice daily for 4 days in Phase 2.

    Drug: Bioflavonoid mouthwash · Drug: Chlorhexidine 0.12% mouthwash

  • Active comparator
    Sequence 2 (Chlorhexidine mouthwash then Bioflavonoid)

    Participants receive Chlorhexidine 0.12% mouthwash twice daily for 4 days in Phase 1, undergo a 15-day washout period, and then receive Bioflavonoid mouthwash twice daily for 4 days in Phase 2.

    Drug: Bioflavonoid mouthwash · Drug: Chlorhexidine 0.12% mouthwash

Interventions

  • DrugFlavonoidsStudies of FlavonoidsFlavonoids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rinsed twice daily for 4 consecutive days. Abstinence from mechanical oral hygiene during use. 15-day washout before/after sequence.

  • DrugChlorhexidineStudies of ChlorhexidineChlorhexidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rinsed twice daily for 4 consecutive days. Abstinence from mechanical oral hygiene during use. 15-day washout before/after sequence.

06

What researchers measure

Primary outcomes

  1. Total plaque accumulation

    Plaque levels were recorded using the Turesky modification of the Quigley and Hein plaque index (TQHPI). Scores range from 0 to 5, where 0 = no plaque and 5 = plaque covering two-thirds or more of the crown surface. Higher scores indicate greater plaque accumulation.

    Time frame: Day 4 of Phase 1 and Day 4 of Phase 2

  2. Gingival Inflammation Score

    Gingival inflammation was evaluated on the buccal and lingual surfaces using the Loe Gingival Index via gentle probing. Scoring criteria was defined as: 0= normal gingiva, 1= mild inflammation- slight change in color, oedema no bleeding on probing, 2= moderate inflammation- redness, oedema, bleeding on probing, 3= severe inflammation- marked redness, oedema, ulceration, tendency to spontaneous bleeding.

    Time frame: Day 1 and Day 4 of Phase 1; Day 1 and Day 4 of Phase 2

Secondary outcomes

  1. Participant User Experience Questionnaire

    Evaluated using a 6-item questionnaire adapted to assess participant perception across six domains: taste perception, post-rinse taste duration, taste alteration, convenience of use, rinsing duration compliance, and perceived effectiveness on plaque reduction. Each item is measured on a 10 cm Visual Analogue Scale (VAS) ranging from 0 (most negative response/least favorable) to 100 mm (most positive response/most favorable). Individual item scores will be reported separately.

    Time frame: Day 4 of Phase 1 and Day 4 of Phase 2

07

Study locations

1 site
  • Hospital Odontològic Universitat de Barcelona
    Barcelona, Catalonia 08970, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jul 2026, 4 months.

Of 25 phase 4 interventional studies under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 4. This study's 4 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 17, 2026
StartActual
Mar 2, 2026
Primary completionActual
Jul 10, 2026
CompletionActual
Jul 13, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07824388
Responsible party
Mayra Schemel Suarez (PhD, DDS, University of Barcelona) — Principal investigator
First posted
Sep 17, 2026
Start date
Mar 2, 2026
Primary completion
Jul 10, 2026
Completion
Jul 13, 2026
Last update
Sep 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Flavonoids · Chlorhexidine

Start the discussion